Mounjaro (tirzepatide, Eli Lilly) is a GLP-1 receptor agonist with a well-characterized safety profile. This article covers common side effects, serious warnings, the boxed-warning context, and when to call a provider — plus the genetic variables that shape baseline GLP-1 biology.

The PlexusDx Precision Peptide Genetic Test analyzes 34 weight management genetic insights — covering 8 peptide pathways, 11 SNPs, and 9 genes including FTO, MC4R, PPARG, TCF7L2, and GIPR. This comprehensive guide explains what each insight cluster covers, which peptide pathways are analyzed, and why genetic specificity is the missing variable in most weight management decisions.

In April 2026, a Nature GWAS of 27,885 GLP-1 medication users found GIPR rs1800437 associated with outcomes specifically in tirzepatide users — not in GLP-1-only agonist users. This article explains what that finding means, why the dual-receptor distinction matters, and why the PlexusDx Precision Peptide Genetic Test directly genotypes this SNP across 34 weight management insights.

A Diabetes Care analysis estimates tirzepatide may reduce MACE risk by up to 28% and all-cause mortality by 39% compared to theoretical placebo — a figure the SURPASS-CVOT trial design couldn't directly show. Here's what the imputed placebo data reveals, and why GLP-1 receptor pathway genetics matter before any weight management decision.